Is PFS recognised by regulators?

Partly. The Swedish Medical Products Agency, the Italian regulator and Health Canada have noted persistent post-treatment effects in patient information. The U.S. FDA updated finasteride labelling in 2011 and 2012 to mention persistent erectile dysfunction. The clinical research community remains divided on whether PFS is a single mechanism or a heterogeneous group of overlapping presentations.

Will a hormone panel diagnose PFS?

No, in the strict sense. PFS is a clinical diagnosis based on history and symptoms. A hormone panel is what you run to make sure something else isn't being missed — primary or secondary hypogonadism, hyperprolactinaemia, thyroid dysfunction, or markedly altered SHBG. Not all of those are 'PFS' but all of them have actionable interventions.

Does finasteride affect testosterone long-term?

Finasteride blocks 5α-reductase, lowering DHT but raising total testosterone modestly during treatment. After stopping, hormones typically return toward pre-treatment levels in most men. A subset reports persistent symptoms despite lab values inside the reference range — the unresolved question of PFS.

← All articles

FinasteridePFSHormonesAndrology

Post-Finasteride Syndrome: what we know, what we don't, and what to measure

PFS is a contested clinical entity with very real symptoms for some patients. Here is the honest summary of the evidence, what hormone testing actually shows after stopping finasteride, and where the data ends.

FutureKit Medical & Science Team

In-house research, written against ESHRE and AUA clinical guidance

Published 2026-04-28

KEY TAKEAWAYS

What to remember before reading on.

1
Post-Finasteride Syndrome (PFS) describes persistent sexual, neurological and emotional symptoms that some men report after stopping finasteride. It is recognised as a clinical entity by some regulatory bodies and remains contested by others.
2
A standard hormone panel is not diagnostic for PFS. Many patients have hormone values inside the typical adult range; the symptom-marker correlation is weaker than the symptom severity.
3
What a panel does answer: whether finasteride alone explains the picture, or whether something else (low total T, hypogonadism, prolactinoma) needs investigating.
4
If you took finasteride and have unresolved symptoms, the right next step is data — a hormone baseline, a clinician familiar with PFS, and a documented timeline.

What PFS is

Post-Finasteride Syndrome (PFS) is the term used for persistent symptoms that a subset of men report after stopping finasteride — a 5α-reductase inhibitor used for male-pattern hair loss (1 mg) and benign prostatic hyperplasia (5 mg).

The reported symptoms span three domains:

Sexual: persistent erectile dysfunction, low libido, reduced ejaculate volume, anhedonic orgasm.
Neurological / cognitive: depression, anxiety, brain fog, sleep disturbance, anhedonia.
Physical: muscle atrophy, gynecomastia, persistent skin or genital changes.

Symptoms are described as persisting weeks, months, or — in the most-reported cases — years after discontinuation. The contested points are: what fraction of finasteride users develop persistent symptoms, what mechanism underlies the persistence, and whether all PFS reports describe one syndrome or a heterogeneous mix.

What the evidence base looks like

The evidence is uneven by domain.

Persistent erectile dysfunction. This is the best-documented persistent effect. Multiple cohort studies and the FDA's 2012 labelling update reflect a real (if uncommon) signal. Estimates of prevalence vary widely, from 1.4% to 5% of men exposed, with much higher rates in self-selected reporting populations.

Persistent depression and anxiety. A handful of observational studies and pharmacovigilance databases (FAERS, EudraVigilance) show elevated reporting. The challenge is that depression and anxiety are also background-prevalent in the patient population (men using finasteride for hair loss are disproportionately younger and self-selected). Causation is harder to establish than correlation.

Sexual function and ejaculate volume. Reproducible in case series; the mechanism likely involves altered DHT signalling at peripheral tissue, possibly with downstream effects on neurosteroid synthesis.

Mechanistic theories. The leading candidates: (a) altered neurosteroid synthesis (allopregnanolone, etc.) with persistent CNS effects; (b) androgen receptor sensitivity changes; (c) epigenetic changes from chronic 5α-reductase inhibition. None are definitively established.

The field needs prospective controlled studies; the existing data is overwhelmingly retrospective and cohort-based.

What hormone testing shows

A standard hormone panel — total + free testosterone, FSH, LH, SHBG, prolactin, estradiol — is not diagnostic for PFS. The complication is that:

Many patients with debilitating PFS symptoms have hormone values inside the reference range.
Some have low total testosterone, which is interpretable as hypogonadism in its own right.
A subset have elevated prolactin or shifted SHBG, which is interpretable as something else and treatable.

What a panel actually does:

Rules in or rules out hypogonadism. Low total testosterone with high LH = primary; with low LH = secondary. Either is a different conversation than PFS.
Catches the secondary causes that imitate PFS. Hyperprolactinaemia produces low libido, ED, and mood symptoms — and is treatable. Missing it means treating "PFS" when the real diagnosis is a prolactinoma.
Establishes a baseline for tracking. Even if the panel is unremarkable, having documented values gives you something to compare against in 6 or 12 months.

For the man with persistent symptoms after finasteride, the panel is necessary — not sufficient.

What to do if you took finasteride and have unresolved symptoms

Three practical steps, in order:

One: document the timeline. When did you start, when did you stop, when did symptoms appear, when did they persist or worsen. This is the single most useful thing for any clinician you eventually see. Without it, the case is anecdote.

Two: run a hormone panel. Two morning samples, fasted, two to four weeks apart. The six markers above. The point is not to "prove PFS" — it's to characterise the hormonal landscape and rule out treatable alternatives. Bring the printable PDF to whatever clinician you see.

Three: find a clinician who is familiar with the literature. That is a smaller pool than it should be. Andrology and endocrinology subspecialists are the most likely starting points. The PFS Foundation and PFS-aware physician networks publish referral lists in some countries. A clinician dismissive of the entity is not necessarily wrong about your specific case, but they're unlikely to do useful work on it.

Where this site can and can't help

We can give you the panel: six markers, ISO-certified German lab, physician interpretation that reads the markers in clinical context. The Hormone Panel 01 is what we're built for. We can also point you at the biomarker reference pages for the longer clinical detail per marker.

We cannot diagnose PFS. We're a screening test, not a specialist clinic. For the symptom-side workup, the right move is a clinician with the time and the literature.

If you took finasteride and you're reading this because something hasn't gone back to normal, the data says: you're not alone, the picture is more complicated than the prescribers tend to admit, and starting with a baseline is rarely the wrong move.

FAQ